A phase Ib study of lumretuzumab, a glycoengineered...

Annals of Oncology 2016 / 10 Vol. 27; Iss. suppl_6

A phase Ib study of lumretuzumab, a glycoengineered monoclonal antibody targeting HER3, in combination with carboplatin and paclitaxel as 1st-line treatment in patients with squamous non-small cell lung cancer

Cejalvo, J.M., Fleitas, T., Felip, E., Mendivil, A. Navarro, Martinez-Garcia, M., Taus, A., Leighl, N., Lassen, U., Soerensen, M. Mau, Adessi, C., Michielin, F., Jacob, W., James, I., Ceppi, M., Weiss
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
27
Language:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdw368.15
Date:
October, 2016
File:
PDF, 39 KB
english, 2016
Conversion to is in progress
Conversion to is failed